PTGX – Protagonist Therapeutics Inc
Protagonist Therapeutics, Inc.PTGX
$82.27Name : Protagonist Therapeutics, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $5,143,163,392.00
EPSttm : 0.66
Protagonist Therapeutics, Inc.
$82.27
2.27%$1.91Float Short %
11.07
Margin Of Safety %
-19
Put/Call OI Ratio
0.06
EPS Next Q Diff
0.19
EPS Last/This Y
-6.34
EPS This/Next Y
2.93
Price
82.25
Target Price
95.92
Analyst Recom
1.23
Performance Q
28.27
Relative Volume
0.65
Beta
2.27
Ticker: PTGX
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-12-08 | PTGX | 89.77 | 0.06 | 0.00 | 14211 |
| 2025-12-09 | PTGX | 88.58 | 0.06 | 0.01 | 14276 |
| 2025-12-10 | PTGX | 91.9 | 0.06 | 0.27 | 14572 |
| 2025-12-11 | PTGX | 92.18 | 0.06 | 0.00 | 14888 |
| 2025-12-12 | PTGX | 95.37 | 0.06 | 0.02 | 15041 |
| 2025-12-15 | PTGX | 94.82 | 0.06 | 0.01 | 15055 |
| 2025-12-16 | PTGX | 91.54 | 0.06 | 0.05 | 15082 |
| 2025-12-17 | PTGX | 89.44 | 0.06 | 0.02 | 15105 |
| 2025-12-18 | PTGX | 85.81 | 0.06 | 0.02 | 15312 |
| 2025-12-19 | PTGX | 86.04 | 0.06 | 0.02 | 15385 |
| 2025-12-22 | PTGX | 87.49 | 0.05 | 0.00 | 14469 |
| 2025-12-23 | PTGX | 88.81 | 0.05 | 0.00 | 14491 |
| 2025-12-26 | PTGX | 88.79 | 0.04 | 0.33 | 14613 |
| 2025-12-29 | PTGX | 87.85 | 0.04 | 0.68 | 14618 |
| 2025-12-30 | PTGX | 87.27 | 0.05 | 0.11 | 14657 |
| 2025-12-31 | PTGX | 87.27 | 0.05 | 0.20 | 15248 |
| 2026-01-02 | PTGX | 87.21 | 0.05 | 0.41 | 15296 |
| 2026-01-05 | PTGX | 84.78 | 0.05 | 0.12 | 15336 |
| 2026-01-06 | PTGX | 82.19 | 0.06 | 0.40 | 15434 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-12-08 | PTGX | 90.25 | -128.3 | - | -1.87 |
| 2025-12-09 | PTGX | 88.56 | -128.3 | - | -1.87 |
| 2025-12-10 | PTGX | 91.37 | -128.3 | - | -1.87 |
| 2025-12-11 | PTGX | 92.20 | -128.3 | - | -1.87 |
| 2025-12-12 | PTGX | 95.25 | -128.3 | - | -1.87 |
| 2025-12-15 | PTGX | 94.79 | -128.3 | - | -1.87 |
| 2025-12-16 | PTGX | 94.79 | -128.3 | - | -1.87 |
| 2025-12-17 | PTGX | 89.33 | -128.3 | - | -1.87 |
| 2025-12-18 | PTGX | 85.70 | -128.3 | - | -1.87 |
| 2025-12-19 | PTGX | 86.03 | -128.3 | - | -1.87 |
| 2025-12-22 | PTGX | 87.70 | -128.3 | - | -1.87 |
| 2025-12-23 | PTGX | 88.93 | -128.3 | - | -1.87 |
| 2025-12-26 | PTGX | 88.84 | -128.3 | - | -1.87 |
| 2025-12-29 | PTGX | 87.92 | -128.3 | - | -1.87 |
| 2025-12-30 | PTGX | 87.27 | -128.3 | - | -1.87 |
| 2025-12-31 | PTGX | 87.32 | -128.3 | - | -1.87 |
| 2026-01-02 | PTGX | 87.22 | -128.3 | - | -1.87 |
| 2026-01-05 | PTGX | 84.27 | -128.3 | - | -1.87 |
| 2026-01-06 | PTGX | 82.25 | -128.3 | - | -1.87 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-12-08 | PTGX | -2.98 | -0.26 | 9.45 |
| 2025-12-09 | PTGX | -2.98 | -0.26 | 9.45 |
| 2025-12-10 | PTGX | -2.98 | -0.26 | 9.96 |
| 2025-12-11 | PTGX | -2.98 | -0.26 | 9.96 |
| 2025-12-12 | PTGX | -2.43 | -0.26 | 9.96 |
| 2025-12-15 | PTGX | -2.43 | -0.27 | 9.96 |
| 2025-12-16 | PTGX | -2.44 | -0.27 | 9.96 |
| 2025-12-17 | PTGX | -2.44 | -0.27 | 9.96 |
| 2025-12-18 | PTGX | -2.44 | -0.27 | 9.96 |
| 2025-12-19 | PTGX | -2.44 | -0.27 | 9.96 |
| 2025-12-22 | PTGX | -2.44 | -0.27 | 9.96 |
| 2025-12-23 | PTGX | -2.44 | -0.27 | 9.96 |
| 2025-12-26 | PTGX | -2.44 | -0.27 | 11.07 |
| 2025-12-29 | PTGX | -2.44 | -0.26 | 11.07 |
| 2025-12-30 | PTGX | -2.44 | -0.26 | 11.07 |
| 2025-12-31 | PTGX | -2.44 | -0.26 | 11.07 |
| 2026-01-02 | PTGX | -2.44 | -0.26 | 11.07 |
| 2026-01-05 | PTGX | -2.44 | -0.26 | 11.07 |
| 2026-01-06 | PTGX | -2.44 | -0.26 | 11.07 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-0.62
Avg. EPS Est. Current Quarter
-0.56
Avg. EPS Est. Next Quarter
-0.43
Insider Transactions
-2.44
Institutional Transactions
-0.26
Beta
2.27
Average Sales Estimate Current Quarter
34
Average Sales Estimate Next Quarter
18
Fair Value
66.73
Quality Score
53
Growth Score
59
Sentiment Score
55
Actual DrawDown %
14.8
Max Drawdown 5-Year %
-85.8
Target Price
95.92
P/E
129.89
Forward P/E
96.84
PEG
P/S
24.58
P/B
7.96
P/Free Cash Flow
80.73
EPS
0.63
Average EPS Est. Cur. Y
-1.87
EPS Next Y. (Est.)
1.06
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
21.94
Relative Volume
0.65
Return on Equity vs Sector %
-20
Return on Equity vs Industry %
-4.8
EPS 1 7Days Diff
EPS 1 30Days Diff
EBIT Estimation
Protagonist Therapeutics, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 128
Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide therapeutics for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide, an injectable mimetic of hepcidin that is in phase 3 clinical trials for the treatment of polycythemia vera; Icotrokinra, an orally delivered investigational drug which is in phase 3 clinical trials indicated to block biological pathways targeted by marketed injectable antibody drugs; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company also develops IL-17 oral peptide antagonist PN-88,1 an oral metabolic/obesity peptide program, and an oral hepcidin mimetic/ferroportin blocker that is in pre-clinical stage. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.
stock quote shares PTGX – Protagonist Therapeutics Inc Stock Price stock today
news today PTGX – Protagonist Therapeutics Inc stock forecast ,stock prediction 2023 2024 2025
marketwatch PTGX – Protagonist Therapeutics Inc yahoo finance google finance
stock history PTGX – Protagonist Therapeutics Inc invest stock market
stock prices PTGX premarket after hours
ticker PTGX fair value insiders trading